Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required)
Funding Opportunity RFA-DK-20-501 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of typ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 23, 2020 Category: Research Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
Funding Opportunity RFA-DK-20-502 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of typ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 23, 2020 Category: Research Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the en...
Source: NIDDK Funding Opportunities - January 23, 2020 Category: Endocrinology Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either weight loss through lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the en...
Source: NIDDK Funding Opportunities - January 23, 2020 Category: Endocrinology Source Type: funding
The Biological Mechanisms of Metformin Effects on Aging and Longevity (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AG-20-044 from the NIH Guide for Grants and Contracts. This FOA invites applications on novel studies of the molecular mechanisms underlying metformins effects on aging and longevity. The goal of this FOA is to support applications that will lead to an in-depth understanding of the molecular mechanisms that determine the effects of metformin, either beneficial or detrimental, in relation to aging and longevity. Research supported by this FOA should lead to new insights and better understanding of metformins effects on aging and aging-related diseases. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 7, 2019 Category: Research Source Type: funding
Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01 Clinical Trial Optional)
The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets. (Source: N...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2017 Category: Research Source Type: funding
Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01)
The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets. Version: ...
Source: Grants.gov - December 10, 2016 Category: Research Tags: Education Health Source Type: funding
Potential Effects of Metformin on Aging and Age-Related Conditions: Small-Scale Clinical Studies and Secondary Analysis of Controlled Clinical Studies (R01)
The objective of this FOA is to support research projects (R01), including small-scale physiologic studies in humans or secondary analyses of data and/or stored biospecimens from controlled clinical intervention studies, to increase our understanding of the clinical translational potential of metformin to delay deleterious aging changes or to extend healthy human life span. This includes identification of specific populations particularly likely to benefit from treatment, and/or obtaining information on metformins human physiologic and cellular effects that would be useful in identifying novel molecular targets. (Source: N...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 9, 2016 Category: Research Source Type: funding
Limited Competition: Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study (U01)
Funding Opportunity ID: 286672 Opportunity Number: RFA-DK-16-511 Opportunity Title: Limited Competition: Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study (U01)Opportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: Cooperative AgreementCategory of Funding Activity: Food and NutritionHealthCategory Explanation: CFDA Number(s): 93.847Eligible Applicants: State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State co...
Source: Grants.gov - July 28, 2016 Category: Research Tags: Food and Nutrition Health Source Type: funding
Limited Competition: Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study (U01)
Funding Opportunity RFA-DK-16-511 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue treatment and follow-up of the participants recruited into the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study. GRADE is a pragmatic, unmasked clinical trial to compare commonly used diabetes medications, when combined with metformin, on long-term glucose-lowering effectiveness, with the main goal of providing guidance to clinicians about the most appropriate medications to treat type 2 diabetes. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - July 28, 2016 Category: Research Source Type: funding
Limited Competition: Continuation of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01)
Funding Opportunity Number: RFA-DK-15-504 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants State governmentsCounty governmentsCity or township governmentsSpecial district governmentsIndependent school districtsPublic and State controlled institutions of higher educationNative American tribal governments (Federally recognized)Public housing authorities/Indian housing authoritiesNative American tribal organizations (other than Federally recognized tribal governments)Nonprofits ha...
Source: Grants.gov - March 19, 2015 Category: Research Tags: Food and Nutrition Health Source Type: funding
Limited Competition: Continuation of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study (U01)
Funding Opportunity RFA-DK-15-504 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to continue the follow-up of the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort through a cooperative agreement. TODAY was a multi-center controlled clinical trial examining the efficacy of three approaches to treat recently diagnosed type 2 diabetes in youth aged 10-17 years. TODAY demonstrated that combination therapy with metformin plus rosiglitazone sustained glycemic control longer than either metformin plus an intensive lifestyle program or m...
Source: NIH Funding Opportunities (Notices, PA, RFA) - March 17, 2015 Category: Research Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01)
Funding Opportunity Number: RFA-DK-15-503 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants Public and State controlled institutions of higher educationPrivate institutions of higher educationAgency Name: HHS-NIH11Closing Date: Apr 09, 2015Award Ceiling: Expected Number of Awards: 21Creation Date: Feb 06, 2015Funding Opportunity Description: The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes P...
Source: Grants.gov - February 7, 2015 Category: Research Tags: Food and Nutrition Health Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (Collaborative U01)
Funding Opportunity Number: RFA-DK-15-505 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: Food and NutritionHealthCFDA Number: 93.847Eligible Applicants Public and State controlled institutions of higher educationPrivate institutions of higher educationAgency Name: HHS-NIH11Closing Date: Apr 09, 2015Award Ceiling: Expected Number of Awards: 1Creation Date: Feb 06, 2015Funding Opportunity Description: The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Pr...
Source: Grants.gov - February 7, 2015 Category: Research Tags: Food and Nutrition Health Source Type: funding
Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01)
Funding Opportunity RFA-DK-15-503 from the NIH Guide for Grants and Contracts. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 5...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 6, 2015 Category: Research Source Type: funding
